Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells.

Cancer letters - 28 Feb 2021

Hartman Mariusz L, Gajos-Michniewicz Anna, Talaj Julita A, Mielczarek-Lewandowska Aleksandra, Czyz Malgorzata

Abstract excerpt

BRAFV600- and MEK1/2-targeting therapies rarely produce durable response in melanoma patients. We investigated five BRAFV600E melanoma cell lines derived from drug-naïve tumor specimens to assess cell death response to encorafenib (Braftovi), a recently FDA-approved BRAFV600 inhibitor. Drug-naïve cell lines (i) did not harbor damaging alterations in genes encoding core apoptotic machinery, but they differed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-2-Associated X Protein
Share to bcl-X Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Drug Screening Assays, Antitumor

Share to Drug Synergism

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Proto-Oncogene Proteins c-bcl-2

Share to Sulfonamides

Source

Identifiers

PMID: 33259900
DOI: 10.1016/j.canlet.2020.11.036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells.PMID 33259900Read ↗

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 MimeticsSemantic proximity Read ↗

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsSemantic proximity Read ↗

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survivalSemantic proximity Read ↗

The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.Semantic proximity Read ↗

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivitySemantic proximity Read ↗

<i>BCL2A1</i> is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibitionSemantic proximity Read ↗

Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.Semantic proximity Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

The BCL-2 arbiters of apoptosis and their growing role as cancer targetsSemantic proximity Read ↗

BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of ApoptosisSemantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.